ALNY Q2 2019 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$45M+49.5% YoY

Gross Profit

$40M90.3% margin

Operating Income

-$236M-528.4% margin

Net Income

-$219M-490.9% margin

EPS (Diluted)

$-2.02

QoQ Revenue Growth

+34.3%

Cash Flow

Operating Cash Flow

$289M

Free Cash Flow

$267M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$2.7B

Total Liabilities

$959M

Stockholders' Equity

$1.8B

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$30M	+49.5%
Gross Profit	$40M	$30M	+35.0%
Operating Income	-$236M	-$192M	-22.8%
Net Income	-$219M	-$164M	-34.2%

Revenue Segments

Product

$38M100%

Geographic Segments

UNITED STATES

$28M74%

Non-US Or Europe

$10M26%